RxDoctor Payments Data

Manuel Pun, MD

Cardiovascular Disease · Trumbull, CTNPI 1205833167

Payments from drug & device makers

$10,112in general payments, 2019–2025

Across 62 payments — averaging $163.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$6K
  • Boehringer Ingelheim$1K
  • AstraZeneca$458
  • Esperion Therapeutics, Inc.$360
  • Merck$253
  • Lilly USA, LLC$252
  • plus $1K from 10 others

What the payments were for

  • Speaking & faculty fees$4,40044%
  • Food & beverage$5,68156%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,112 in reported general payments places this provider in the 80th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$60,729
Medicare patients
342
Services billed
791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$39,705
XareltoRivaroxaban41$38,715
EntrestoSacubitril/Valsartan33$31,738
Repatha SureclickEvolocumab11$6,203
Metoprolol Succinate84$1,378
Ezetimibe28$373
Valsartan22$373
Atorvastatin Calcium25$284
Furosemide32$268
Atenolol14$251
Lisinopril27$234
Spironolactone23$210
Rosuvastatin Calcium25$179
Amlodipine Besylate31$168
Carvedilol32$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$39,70530 claims
Johnson & JohnsonXarelto$242$38,71541 claims
NovartisEntresto$177$31,73833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Trumbull

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →